Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.40 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | CMA1 | P23946 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376105 | 0.88 | MAPK1 (0.40) | ROCK2ROCK1 | |
| SCHEMBL4368655 | 0.83 | TRPV1 (0.38) | TRPV1ROCK2ROCK1 | |
| SCHEMBL4367880 | 0.82 | ROCK2 (0.39) | ROCK2ROCK1 | |
| SCHEMBL4367897 | 0.82 | ROCK2 (0.39) | ROCK2ROCK1 | |
| SCHEMBL4375050 | 0.80 | EGLN1 (0.41) | ROCK2ROCK1 | |
| SCHEMBL4369500 | 0.79 | MAPT (0.34) | ROCK2ROCK1 | |
| SCHEMBL4368955 | 0.79 | METAP1 (0.32) | — | |
| Trifluoroacetic Acid SCHEMBL4371839 | 0.79 | METAP1 (0.43) | TRPV1IDH1HDAC3CYP2C9HDAC1 | |
| SCHEMBL4372975 | 0.78 | MTOR (0.40) | CYP2C9ROCK2ROCK1 | |
| SCHEMBL4375234 | 0.78 | MTOR (0.40) | CYP2C9ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622592-B2 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20060036098-A1 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060036098-A1 | Carbonylamino-benzimidazole derivatives as androgen receptor modulators | AR, SHBG, BRCA1 | TRPV1 2848/4885IDH1 2649/4885HDAC3 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.